ADHD / Focus & Attention
Attention deficit and focus-related disorders are characterized by dysregulation of dopamine and norepinephrine signaling in the prefrontal cortex, reduced BDNF (Brain-Derived Neurotrophic Factor) levels, and suboptimal synaptic density. Peptide research in this area focuses on compounds that enhance neurotrophic factor expression, improve dopaminergic tone, reduce anxiety-related cognitive interference, and promote synaptogenesis. The following stack represents the most studied peptides for focus, attention, and cognitive performance.
1. Semax — Primary Nootropic / Dopamine & BDNF Enhancer
Semax is an ACTH(4-7) analog that dramatically upregulates BDNF, NGF, and VEGF in the brain. It increases dopamine and serotonin synthesis and receptor sensitivity in the prefrontal cortex — precisely the area implicated in ADHD. Research shows improved attention span, working memory, and processing speed. It is the cornerstone of this stack.
Dosing Protocol: 300–600 mcg intranasally per day, divided into 1–2 doses (morning and early afternoon). Cycle: 2 weeks on, 1 week off. Avoid late-day dosing as it may be mildly stimulating.
2. Selank — Anxiolytic / Focus Enhancer
Selank is a synthetic analog of tuftsin that modulates the enkephalin system and balances GABA/dopamine ratios. It reduces anxiety-related cognitive interference — a major contributor to attention problems — without sedation or cognitive blunting. Studies show improved memory consolidation and sustained attention. Pairs synergistically with Semax.
Dosing Protocol: 250–750 mcg intranasally per day, split into 1–2 doses. Can be taken in the same sessions as Semax (separate applicators). Cycle with Semax: 2 weeks on, 1 week off.
3. Dihexa — Synaptogenesis / Memory & Learning
Dihexa potentiates HGF/c-Met signaling to dramatically increase synaptogenesis — the formation of new synaptic connections. In animal models it reverses cognitive deficits far more potently than BDNF alone. For attention and learning difficulties, increasing synaptic density in the prefrontal cortex and hippocampus directly addresses the neurological substrate of the problem.
Dosing Protocol: 10–15 mg orally or sublingually, 1–2 times per week (not daily — effects are long-lasting). Use conservatively given limited human data. Take on a separate day from Semax/Selank to assess individual response. Short cycles: 4–6 weeks, then a 4-week break.
4. NAD+ — Mitochondrial Energy / Neuronal Fuel
NAD+ decline is associated with reduced neuronal energy availability and impaired sirtuin activity — both of which worsen cognitive function and attention. IV or SubQ NAD+ supplementation restores mitochondrial efficiency in neurons, supporting sustained mental energy throughout the day. It addresses the “fuel” problem underlying many attention and fatigue issues.
Dosing Protocol: SubQ injection: 50–100 mg daily or every other day. Alternatively, IV infusion 500 mg once weekly as a loading protocol, then monthly maintenance. Best administered in the morning.
This stack attacks focus and attention deficits from four distinct angles: Semax directly boosts dopaminergic tone and BDNF in the prefrontal cortex. Selank clears anxiety-related noise that disrupts sustained attention. Dihexa builds new synaptic infrastructure for improved signal processing. NAD+ ensures neurons have the mitochondrial fuel to sustain cognitive effort. Together they address neurotransmitter balance, synaptic architecture, and cellular energy — the three core pillars of optimal attention.
- Dolotov OV et al. (2008). Semax, an analog of ACTH(4-7), regulates BDNF and VEGF expression and has neuroprotective properties. Brain Research Bulletin. DOI: 10.1016/j.bbr.2007.08.019
- Semenova TP et al. (2015). Selank and memory improvement. Neuroscience & Behavioral Physiology. DOI: 10.1134/S0022093015040037
- Wright JW et al. (2013). Dihexa dramatically potentiates synaptic connectivity. PLOS ONE. DOI: 10.1371/journal.pone.0054648
- Imai S, Guarente L. (2014). NAD+ and sirtuins in aging and neurological disease. Science. DOI: 10.1126/science.1231923
- Kolomin T et al. (2006). Effects of Semax on dopaminergic neurotransmission. Neuroscience Letters. DOI: 10.1016/j.neulet.2006.09.015
Research Use Only. All information on this page is for educational purposes. It is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Research Use Only. All content is for educational purposes only. Not medical advice. Consult a licensed healthcare provider before making health decisions.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).